U.S. and UK to eliminate drug tariffs, boost NHS payments, and improve market access.

GLP-1 drugs, used in humans, are being tested in cats and dogs to treat obesity and diabetes in U.S. and U.K. trials.

Richard Pazdur, FDA’s top cancer drug official, plans to retire by year-end 2025, amid leadership changes at the agency.

Eli Lilly lowered Zepbound prices to boost access, amid competition and demand for GLP-1 obesity drugs.

Wockhardt’s Zaynich, a new antibiotic, gained FDA acceptance, boosting shares and marking a historic milestone for India’s pharma industry.

GE HealthCare and DeepHealth unveiled AI and cloud tools at RSNA 2025 to boost radiology efficiency and accuracy.

Medical Care Technologies launches AI health app in final testing, awaiting Apple approval for global release.

L&T Tech introduces AI-powered digital twin for real-time lung function monitoring using NVIDIA tech.

FDA approves Lupin’s biosimilar Armlupeg to reduce infection risk in chemo patients.

FDA approves Breyanzi CAR T therapy for relapsed/refractory marginal zone lymphoma after two prior treatments.